Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Plo

Showing results (71-80 of 124) with videos related to

Pageof 13
Sort By:
Cell Reports|September 12, 2019
MCM8- and MCM9 Deficiencies Cause Lifelong Increased Hematopoietic DNA Damage Driving p53-Dependent Myeloid TumorsMalik Lutzmann, Florence Bernex, Cindy da Costa de Jesus, et al.
Leukemia|February 20, 2024
Deregulation of the p19/CDK4/CDK6 axis in Jak2<sup>V617F</sup> megakaryocytes accelerates the development of myelofibrosisHélène Duparc, Delphine Muller, Laure Gilles, et al.
The Journal of Experimental Medicine|October 19, 2020
JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PMLTracy Dagher, Nabih Maslah, Valérie Edmond, et al.
Iscience|January 15, 2025
Monocytes generated by interleukin-6-treated human hematopoietic stem and progenitor cells secrete calprotectin that inhibits erythropoiesisValentine Marchand, Lucie Laplane, Louis Valensi, et al.
Blood|November 8, 2019
Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasmsChristian A Di Buduo, Vittorio Abbonante, Caroline Marty, et al.
Journal of Cellular and Molecular Medicine|December 21, 2016
Acquired TET2 mutation in one patient with familial platelet disorder with predisposition to AML led to the development of pre-leukaemic clone resulting in T2-ALL and AML-M0Vladimir T Manchev, Hind Bouzid, Iléana Antony-Debré, et al.
Stem Cell Research|March 21, 2020
TET2 haploinsufficiency alters reprogramming into induced pluripotent stem cellsLise Secardin, Cintia Elisabeth Gomez Limia, Antonio di Stefano, et al.
The Journal of Clinical Investigation|April 29, 2021
PPARγ agonists promote the resolution of myelofibrosis in preclinical modelsJuliette Lambert, Joseph Saliba, Carolina Calderon, et al.
Scientific Reports|November 26, 2016
CXCR4/CXCL12 axis counteracts hematopoietic stem cell exhaustion through selective protection against oxidative stressYanyan Zhang, Mallorie Dépond, Liang He, et al.
Hemasphere|June 16, 2021
Induced Pluripotent Stem Cells Enable Disease Modeling and Drug Screening in Calreticulin del52 and ins5 Myeloproliferative NeoplasmsLise Secardin, Cintia Gomez Limia, Suzana da Silva-Benedito, et al.
Pageof 13

Showing results (71-80 of 124) with videos related to

Sort By:
Pageof 13
Cell Reports|September 12, 2019
MCM8- and MCM9 Deficiencies Cause Lifelong Increased Hematopoietic DNA Damage Driving p53-Dependent Myeloid TumorsMalik Lutzmann, Florence Bernex, Cindy da Costa de Jesus, et al.
Leukemia|February 20, 2024
Deregulation of the p19/CDK4/CDK6 axis in Jak2<sup>V617F</sup> megakaryocytes accelerates the development of myelofibrosisHélène Duparc, Delphine Muller, Laure Gilles, et al.
The Journal of Experimental Medicine|October 19, 2020
JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PMLTracy Dagher, Nabih Maslah, Valérie Edmond, et al.
Iscience|January 15, 2025
Monocytes generated by interleukin-6-treated human hematopoietic stem and progenitor cells secrete calprotectin that inhibits erythropoiesisValentine Marchand, Lucie Laplane, Louis Valensi, et al.
Blood|November 8, 2019
Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasmsChristian A Di Buduo, Vittorio Abbonante, Caroline Marty, et al.
Journal of Cellular and Molecular Medicine|December 21, 2016
Acquired TET2 mutation in one patient with familial platelet disorder with predisposition to AML led to the development of pre-leukaemic clone resulting in T2-ALL and AML-M0Vladimir T Manchev, Hind Bouzid, Iléana Antony-Debré, et al.
Stem Cell Research|March 21, 2020
TET2 haploinsufficiency alters reprogramming into induced pluripotent stem cellsLise Secardin, Cintia Elisabeth Gomez Limia, Antonio di Stefano, et al.
The Journal of Clinical Investigation|April 29, 2021
PPARγ agonists promote the resolution of myelofibrosis in preclinical modelsJuliette Lambert, Joseph Saliba, Carolina Calderon, et al.
Scientific Reports|November 26, 2016
CXCR4/CXCL12 axis counteracts hematopoietic stem cell exhaustion through selective protection against oxidative stressYanyan Zhang, Mallorie Dépond, Liang He, et al.
Hemasphere|June 16, 2021
Induced Pluripotent Stem Cells Enable Disease Modeling and Drug Screening in Calreticulin del52 and ins5 Myeloproliferative NeoplasmsLise Secardin, Cintia Gomez Limia, Suzana da Silva-Benedito, et al.
Pageof 13